Hypothesis

Reprogrammed immune lineages derived from aged donors retain epigenetic memory at senescence‑associated secretory phenotype (SASP) regulatory loci, causing them to re‑express pro‑inflammatory factors upon activation and thereby perpetuate systemic aging even in a young host.

Mechanistic Rationale

Induced pluripotent stem cell (iPSC) reprogramming erases most age‑related marks, yet certain enhancers and promoters resist demethylation, especially those bound by lineage‑defining transcription factors such as PU.1 and C/EBPα in myeloid cells 2. If SASP‑driving elements (e.g., IL6, CCL2, CXCL10 enhancers) retain residual DNA methylation or repressive histone marks that become permissive after immune stimulation, reprogrammed macrophages and neutrophils could secrete a SASP indistinguishable from that of naturally senescent immune cells. This would recreate the feed‑forward loop where failing immunosurveillance allows senescent cell accumulation, which further impairs immune function 4.

Experimental Design

1. Cell preparation – Isolate hematopoietic stem cells (HSCs) from 24‑month‑old Ercc1^−/− mice (a model of hematopoietic‑restricted progeria) 1. Reprogram these HSCs to iPSCs, then differentiate them back into myeloid progenitors using established cytokine cocktails.
2. Epigenetic profiling – Perform ATAC‑seq and bisulfite sequencing on SASP promoters/enhancers in (a) native aged HSCs, (b) iPSC‑derived myeloid cells before activation, and (c) the same cells after LPS/IFN‑γ stimulation. Compare to young wild‑type counterparts.
3. Transplantation – Lethally irradiate 2‑month‑old recipients and transplant either (i) iPSC‑derived myeloid cells, (ii) young wild‑type HSCs, or (iii) aged HSCs as controls. Include a senolytic‑treated aged HSC group to benchmark senolysis.
4. Readouts – At 4, 8, and 12 weeks post‑transfer measure: (a) plasma IL‑6, TNF‑α, CCL2 levels; (b) senescence markers (p16^Ink4a^, SA‑β‑gal) in liver, kidney, muscle, and intervertebral discs; (c) frailty index and survival.

Predictions & Falsifiability

• If the hypothesis is true, mice receiving iPSC‑derived myeloid cells will show SASP factor elevations comparable to those receiving aged HSCs, accelerated tissue senescence, and reduced lifespan despite the youthful chronological age of the host.
• If iPSC‑derived immune cells have fully erased epigenetic aging memory, they will behave like young transplants: low circulating SASP, minimal secondary senescence, and survival similar to young HSC recipients.
• A negative result (no difference between iPSC‑derived and young transplants) would falsify the claim that epigenetic scar persists at SASP loci in reprogrammed immune lineages.

Potential Impact

Confirming this mechanism would reveal a hidden barrier to immune rejuvenation strategies and suggest that combinatorial approaches—pairing hematopoietic regeneration with targeted epigenome editing of SASP enhancers—are necessary to break the immune‑driven aging cycle. It would also explain why senolytics alone, which clear existing senescent cells, do not fully ameliorate inflammaging when the immune source remains epigenetically primed to reproduce it.